Vir Biotechnology, Inc.
Clinical trials sponsored by Vir Biotechnology, Inc., explained in plain language.
-
New hope for hepatitis b: experimental drug shows promise in mid-stage trial
Disease control CompletedThis study tested an experimental drug called VIR-2218 in 84 adults with chronic hepatitis B. Some participants received VIR-2218 alone, and others got it combined with pegylated interferon. The main goals were to check safety and how well the drug works against the virus. The st…
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 18, 2026 11:51 UTC
-
New hope for hepatitis b: experimental combo aims to clear the virus
Disease control CompletedThis study tested whether combining two experimental drugs (VIR-2218 and VIR-3434) with or without a standard immune booster (PEG-IFNα) can safely eliminate hepatitis B surface antigen in people with chronic hepatitis B. 244 adults with long-term infection who were already on ant…
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New hope for hepatitis b: experimental therapies aim to suppress the virus
Disease control CompletedThis study tested new experimental treatments for adults with chronic hepatitis B, a long-term liver infection. A total of 33 participants received different combinations of investigational drugs. The main goal was to see if these treatments could lower the virus to undetectable …
Phase: PHASE1, PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 05, 2026 12:05 UTC